Cytek BioSciences Inc (NASDAQ:CTKB) shares, rose in value on Friday, July 11, with the stock price down by -3.09% to the previous day’s close as strong demand from buyers drove the stock to $3.45.
Actively observing the price movement in the last trading, the stock closed the session at $3.56, falling within a range of $3.425 and $3.55. The value of beta (5-year monthly) was 1.259. Referring to stock’s 52-week performance, its high was $7.63, and the low was $2.37. On the whole, CTKB has fluctuated by -0.58% over the past month.
With the market capitalization of Cytek BioSciences Inc currently standing at about $436.98 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CTKB’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CTKB currently trading nearly 2.16% and 7.63% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.54, while the 7-day volatility ratio is showing 5.82% which for the 30-day chart, stands at 6.21%. Furthermore, Cytek BioSciences Inc (CTKB)’s beta value is 1.34.
A comparison of Cytek BioSciences Inc (CTKB) with its peers suggests the former has fared considerably weaker in the market. CTKB showed an intraday change of -3.09% in last session, and over the past year, it shrunk by -46.84%%.
Data on historical trading for Cytek BioSciences Inc (NASDAQ:CTKB) indicates that the trading volumes over the past 10 days have averaged 1.06 and over the past 3 months, they’ve averaged 1.16 million. According to company’s latest data on outstanding shares, there are 127.60 million shares outstanding.
Nearly 9.52% of Cytek BioSciences Inc’s shares belong to company insiders and institutional investors own 60.97% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.09 million shares as on 2025-06-13, resulting in a short ratio of 3.45. According to the data, the short interest in Cytek BioSciences Inc (CTKB) stood at 523.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 4.65 million. The stock has fallen by -39.90% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CTKB stock heading into the next quarter.
